UBS granted Agilent a Buy rating and a $92 price target; Fluidigm a Neutral rating and a $14 price target; and Qiagen a Neutral rating with a $42 price target.
The firm's diagnostics and genomics group saw a 13 percent year-over-year revenue increase in the first quarter.
A busy second day of the JP Morgan conference saw Thermo Fisher's Marc Casper discuss the firm's R&D focus and Exact Sciences' Kevin Conroy discuss plans for Cologuard sales growth.
There were more mergers and acquisitions in the omics space in 2018, reversing the decline experienced in 2017.
Agilent alleges that Twist CEO Emily Leproust and other employees stole trade secrets from it. A trial date has been set for Feb. 24, 2020.
Led by investigators at the University of Trento in Italy, the team received a five-year, £5 million ($6.4 million) award recently to advance its work.
The firm saw growth of 8 percent in its life science business, 9 percent in its crosslabs group, and 9 percent in its diagnostics and genomics division in Q4.
The firm hasn't yet specified how many shares it is offering or at what price but noted that its stock would trade under the Nasdaq symbol TWST.
ACEA's xCELLigence impedance-based, label-free, real-time cell analysis instruments are used in immuno-oncology pre-clinical drug discovery and development.
The New York Times Magazine examines gender discrimination at the Salk Institute.
Science reports that MD Anderson Cancer Center has dismissed three researchers over foreign tie concerns.
A second death in gene therapy trial for type 1 spinal muscular atrophy is under investigation, according to Reuters.
In PLOS this week: antibiotic resistance patterns in Escherichia coli, a dozen genetic loci tied to varicose vein risk, and more.